insights_auto
Why is NVAX down 2.68%?
Dive Deeperchevron_right
NVAX:NASDAQ
Novavax Inc
$8.52
arrow_downward
-2.68%(-0.24) 1D
Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$8.77
High
$9.74
Low
$8.35
Mkt. cap
1.41B
Avg. vol.
8.28M
Volume
4.64M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$0.46
Beta
2.65
Shares outstanding
165.01M
No. of employees
749
Open
$8.77
High
$9.74
Low
$8.35
Mkt. cap
1.41B
Avg. vol.
8.28M
Volume
4.64M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$0.46
Beta
2.65
Shares outstanding
165.01M
No. of employees
749
News stories
From web sources and news partners
News Corp
·
2 days ago
Novavax Inc. stock underperforms Thursday when compared to competitors
TradingView
·
2 days ago
Sunrun, PacBio, and Novavax stocks trade down, what you need to know
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorHealth Care
IndustryBiotechnology
Websitenovavax.com